25 July 2022>: Database Analysis
Integrating Network Pharmacology, Molecular Docking, and Experimental Validation to Investigate the Mechanism of (−)-Guaiol Against Lung Adenocarcinoma
Yaoying Zeng 1E* , Yanbin Pan 1B* , Bo Zhang 1C , Yingbin Luo 1D , Jianhui Tian 1AF , Yuli Wang 1CD , Xudong Ju 2BF , Jianchun Wu 1A* , Yan Li 1A*DOI: 10.12659/MSM.937131
Med Sci Monit 2022; 28:e937131
Figure 8 (A) Cell survival rate was detected by performing a CCK-8 assay. The LUAD cells (A549 and Calu-1) and normal lung cells BEAS-2B cells treated with different concentrations of (−)-Guaiol. IC50 values were 75.7 μM for A549 cells, 92.1 μM for H1299 cells, and 322.3 μM for BEAS-2B cells. Data from 3 independent experiments were represented as means±SD. (B) A549 and Calu-1 were treated with (−)-Guaiol (75 μM) or (−)-Guaiol (75 μM) companied Z-VAD (20μM) for 24 h. ** P<0.01 vs control in A549. # P<0.05 vs (−)-Guaiol in Calu-1. Data from 3 independent experiments were represented as means±SD. (C) A549 and Calu-1 were treated with or without (−)-Guaiol (75 μM) or (−)-Guaiol (75 μM) and Z-VAD (20 μM), and stained with SYTOX Green (100 nM), then observed under a fluorescence microscope.